Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    November 2018
  1. P SANTOS I, van Doorn R, Caspers PJ, Bakker Schut TC, et al
    Improving clinical diagnosis of early-stage cutaneous melanoma based on Raman spectroscopy.
    Br J Cancer. 2018 Nov 9. pii: 10.1038/s41416-018-0257.
    PubMed     Text format     Abstract available


    September 2018
  2. HAMID O, Robert C, Ribas A, Hodi FS, et al
    Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006.
    Br J Cancer. 2018 Sep 11. pii: 10.1038/s41416-018-0207.
    PubMed     Text format     Abstract available


    August 2018
  3. SILVA IPD, Batten M, Long GV
    Reinvigorating tumour-infiltrating lymphocytes from checkpoint inhibitor resistant melanomas.
    Br J Cancer. 2018 Aug 21. pii: 10.1038/s41416-018-0218.
    PubMed     Text format    


  4. KRISP C, Parker R, Pascovici D, Hayward NK, et al
    Proteomic phenotyping of metastatic melanoma reveals putative signatures of MEK inhibitor response and prognosis.
    Br J Cancer. 2018 Aug 17. pii: 10.1038/s41416-018-0227.
    PubMed     Text format     Abstract available


    July 2018
  5. LIPPLAA A, Fernandes R, Marshall A, Lorigan P, et al
    25-hydroxyvitamin D serum levels in patients with high risk resected melanoma treated in an adjuvant bevacizumab trial.
    Br J Cancer. 2018 Jul 23. pii: 10.1038/s41416-018-0179.
    PubMed     Text format     Abstract available


  6. DUPUIS F, Lamant L, Gerard E, Torossian N, et al
    Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
    Br J Cancer. 2018 Jul 5. pii: 10.1038/s41416-018-0168.
    PubMed     Text format     Abstract available


    June 2018
  7. WAGNER NB, Forschner A, Leiter U, Garbe C, et al
    S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
    Br J Cancer. 2018 Jun 28. pii: 10.1038/s41416-018-0167.
    PubMed     Text format     Abstract available


  8. TIBES R, Borad MJ, Dutcus CE, Reyderman L, et al
    Safety, pharmacokinetics, and preliminary efficacy of E6201 in patients with advanced solid tumours, including melanoma: results of a phase 1 study.
    Br J Cancer. 2018 Jun 5. pii: 10.1038/s41416-018-0099.
    PubMed     Text format     Abstract available


    May 2018
  9. ADLER NR, Wolfe R, McArthur GA, Kelly JW, et al
    Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.
    Br J Cancer. 2018 May 14. pii: 10.1038/s41416-018-0088.
    PubMed     Text format     Abstract available


    March 2018
  10. SCHOLZ SL, Cosgarea I, Susskind D, Murali R, et al
    NF1 mutations in conjunctival melanoma.
    Br J Cancer. 2018 Mar 21. pii: 10.1038/s41416-018-0046.
    PubMed     Text format     Abstract available


  11. DEL RE M, Marconcini R, Pasquini G, Rofi E, et al
    PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC.
    Br J Cancer. 2018 Mar 6. pii: bjc20189. doi: 10.1038/bjc.2018.
    PubMed     Text format     Abstract available


    February 2018
  12. DRENO B, Ascierto PA, Atkinson V, Liszkay G, et al
    Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAF(V600) mutation-positive melanoma.
    Br J Cancer. 2018 Feb 13. pii: bjc2017488. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  13. HECHT M, Meier F, Zimmer L, Polat B, et al
    Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.
    Br J Cancer. 2018 Feb 13. pii: bjc2017489. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2018
  14. VAN LAAR R, Lincoln M, Van Laar B
    Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
    Br J Cancer. 2018 Jan 23. pii: bjc2017477. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    December 2017
  15. WU CE, Esfandiari A, Ho YH, Wang N, et al
    Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Br J Cancer. 2017 Dec 12. pii: bjc2017433. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    November 2017
  16. HUGDAHL E, Kalvenes MB, Mannelqvist M, Ladstein RG, et al
    Prognostic impact and concordance of TERT promoter mutation and protein expression in matched primary and metastatic cutaneous melanoma.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  17. ZUGNA D, Senetta R, Osella-Abate S, Fierro MT, et al
    Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients.
    Br J Cancer. 2017 Nov 9. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    September 2017
  18. CIRILLO N, Morgan DJ, Pedicillo MC, Celentano A, et al
    Characterisation of the cancer-associated glucocorticoid system: key role of 11beta-hydroxysteroid dehydrogenase type 2.
    Br J Cancer. 2017;117:984-993.
    PubMed     Text format     Abstract available


    August 2017
  19. ADLER NR, Wolfe R, Kelly JW, Haydon A, et al
    Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Br J Cancer. 2017 Aug 8. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  20. KUZU OF, Gowda R, Noory MA, Robertson GP, et al
    Modulating cancer cell survival by targeting intracellular cholesterol transport.
    Br J Cancer. 2017;117:513-524.
    PubMed     Text format     Abstract available


    July 2017
  21. BOIA-FERREIRA M, Basilio AB, Hamasaki AE, Matsubara FH, et al
    TCTP as a therapeutic target in melanoma treatment.
    Br J Cancer. 2017 Jul 27. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


  22. WASTER P, Orfanidis K, Eriksson I, Rosdahl I, et al
    UV radiation promotes melanoma dissemination mediated by the sequential reaction axis of cathepsins-TGF-beta1-FAP-alpha.
    Br J Cancer. 2017 Jul 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    May 2017
  23. PARAKH S, Park JJ, Mendis S, Rai R, et al
    Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.
    Br J Cancer. 2017;116.
    PubMed     Text format     Abstract available


  24. AMIT M, Tam S, Abdelmeguid AS, Roberts DB, et al
    Mutation status among patients with sinonasal mucosal melanoma and its impact on survival.
    Br J Cancer. 2017 May 11. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    April 2017
  25. NOSRATI A, Tsai KK, Goldinger SM, Tumeh P, et al
    Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapy.
    Br J Cancer. 2017;116:1141-1147.
    PubMed     Text format     Abstract available


    March 2017
  26. BOWYER S, Prithviraj P, Lorigan P, Larkin J, et al
    Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  27. IMAFUKU K, Yoshino K, Yamaguchi K, Tsuboi S, et al
    Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy'.
    Br J Cancer. 2017 Mar 21. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  28. RUSHTON L, Hutchings SJ
    Reply to 'Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'' - outdoor occupation may not be linked to increased risk of melanoma in Britain.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  29. GRANT WB
    Comment on 'The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation'.
    Br J Cancer. 2017 Mar 16. doi: 10.1038/bjc.2017.
    PubMed     Text format    


  30. MALAPELLE U, Mayo de-Las-Casas C, Rocco D, Garzon M, et al
    Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Br J Cancer. 2017;116:802-810.
    PubMed     Text format     Abstract available


  31. KINSLER VA, O'Hare P, Jacques T, Hargrave D, et al
    MEK inhibition appears to improve symptom control in primary NRAS-driven CNS melanoma in children.
    Br J Cancer. 2017 Mar 2. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    January 2017
  32. DAUD A, Kluger HM, Kurzrock R, Schimmoller F, et al
    Phase II randomised discontinuation trial of the MET/VEGF receptor inhibitor cabozantinib in metastatic melanoma.
    Br J Cancer. 2017 Jan 19. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  33. RUSHTON L, Hutchings SJ
    The burden of occupationally-related cutaneous malignant melanoma in Britain due to solar radiation.
    Br J Cancer. 2017 Jan 17. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  34. DALY LE, Power DG, O'Reilly A, Donnellan P, et al
    The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma.
    Br J Cancer. 2017 Jan 10. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    November 2016
  35. HUBNER J, Waldmann A, Geller AC, Weinstock MA, et al
    Interval cancers after skin cancer screening: incidence, tumour characteristics and risk factors for cutaneous melanoma.
    Br J Cancer. 2016 Nov 29. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  36. LI X, Liang L, Feng YA, De Vivo I, et al
    Height, height-related SNPs, and risk of non-melanoma skin cancer.
    Br J Cancer. 2016 Nov 15. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    October 2016
  37. KAUR A, Webster MR, Weeraratna AT
    In the Wnt-er of life: Wnt signalling in melanoma and ageing.
    Br J Cancer. 2016 Oct 20. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  38. CARLINO MS, Vanella V, Girgis C, Giannarelli D, et al
    Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  39. GUPTA A, Roberts C, Tysoe F, Goff M, et al
    RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.
    Br J Cancer. 2016 Oct 6. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


  40. KHOJA L, Kibiro M, Metser U, Gedye C, et al
    Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients.
    Br J Cancer. 2016 Oct 4. doi: 10.1038/bjc.2016.
    PubMed     Text format     Abstract available


    September 2016
  41. TITTARELLI A, Guerrero I, Tempio F, Gleisner MA, et al
    Overexpression of connexin 43 reduces melanoma proliferative and metastatic capacity.
    Br J Cancer. 2016 Sep 22. doi: 10.1038/bjc.2016.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: